Document Detail


Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group.
MedLine Citation:
PMID:  3889818     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The safety and efficacy of captopril therapy in children with severe and refractory hypertension has been evaluated in a collaborative international study which enrolled a group of 73 patients, 15 years of age or younger. Most patients had hypertension associated with renal disease or vascular abnormalities. Captopril was administered for periods of less than 3 months to more than 1 year. A significant decrease in both systolic and diastolic blood pressures was produced by the administration of captopril, usually in conjunction with other antihypertensive agents (most commonly diuretics and/or beta-blockers). Systolic blood pressures were normalized in 62% and 53% and diastolic blood pressures in 56% and 45% of reported patients after the second and sixth months of captopril therapy, respectively. The response to captopril was sustained over a 12-month period. Adverse reactions were reported in 49% of the 73 patients; 48% of patients had experienced adverse reactions to other antihypertensive agents prior to entering the study. The reactions most frequently observed during captopril therapy were hypotension, vomiting, postural symptoms, anemia, rash, and anorexia. Leukopenia was reported in six patients, all of whom had renal impairment. Two of these patients had received concomitant therapy with immunosuppressants, and one had systemic lupus erythematosus. Captopril was discontinued in two of these six children. Statistically significant increases in mean serum urea nitrogen and potassium concentrations and decreases in mean serum CO2 levels were observed during the course of therapy. These effects could not be exclusively attributed to captopril administration as the study population received multidrug therapy and had significant intrinsic disease. Captopril was demonstrated to be an effective and safe drug for the treatment of children with severe hypertension.
Authors:
B L Mirkin; T J Newman
Related Documents :
17824808 - Contribution of captopril thiol group to the prevention of spontaneous hypertension.
17037008 - Proper use of phosphodiesterase inhibitors according to the situations.
2193808 - Haemodynamic effects of ace inhibitors.
16830788 - The antihypertensive activity of angiotensin-converting enzyme inhibitory peptide conta...
6711998 - Passive respiratory mechanics in newborns and children.
9386108 - Postischemic administration of succinate reverses the impairment of oxidative phosphory...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pediatrics     Volume:  75     ISSN:  0031-4005     ISO Abbreviation:  Pediatrics     Publication Date:  1985 Jun 
Date Detail:
Created Date:  1985-07-22     Completed Date:  1985-07-22     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1091-100     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Antihypertensive Agents / administration & dosage,  therapeutic use
Captopril / administration & dosage,  adverse effects,  pharmacology,  therapeutic use*
Child
Child, Preschool
Drug Therapy, Combination
Female
Humans
Hypertension / drug therapy*
Infant
Kidney / drug effects
Male
Proline / analogs & derivatives*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 147-85-3/Proline; 62571-86-2/Captopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Changes in superior sagittal sinus blood velocities due to postural alterations and pressure on the ...
Next Document:  Maternal recognition of pregnancy--a review of the literature.